Raya Therapeutic, Inc. Press Releases

• Published on January 9, 2025 - 16:00 GMT

  

  Raya Therapeutic Announces 9 Orphan Drug Designations Across its 5 Clinical Stage Compounds

  The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS) & other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, January 9, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on December 5, 2024 - 15:00 GMT

  

  Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8

  Dr. Paul Lingor to present Phase 2 ROCK-ALS study. Raya also presenting promising new preclinical data of a combination of two new chemical entities (NCEs). MONTREAL, QUEBEC, CANADA, December 5, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on October 17, 2024 - 12:31 GMT

  

  Raya Therapeutic Announces Publication in The Lancet Neurology of ROCK-ALS Study Data for Fasudil in ALS

  Phase 2 trial showed Fasudil is safe and tolerable and provided evidence to support further investigation as a potential disease-modifying treatment for ALS. MONTREAL, QUEBEC, CANADA, October 17, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...